일본 신약 재심사 제도의 개정 현황 및 시사점 : 리얼월드데이터(Real-World Data)의 활용을 중심으로
Recent Reforms in Japan’s Drug Re-examination System and its Implications : Focusing on Using Real-World Data
The drug re-examination system that is being used in Korea and Japan is aimed to reconfirm the effectiveness and safety of drugs at the end of the predetermined period after approval. As clinical trials before marketing are difficult to find all potential risks, the post-marketing study is necessary. The Drug Use-Results Survey (DURS) is aimed at patients who prescribed the drugs to collect the effectiveness and safety information of the drugs. However, the survey continued to raise the limitation that there was no comparison group. Recently, Real-World Data (RWD) is being used for post-marketing surveillance worldwide. Japan revised the drug re-examination system to include database study using RWD and postmarketing observational study with primary data collection in the comparative cohort study in 2017. This paper addresses the background and contents of revised Japan's re-examination system and the implications of this change for the post-marketing study in Korea.
목차
Abstract 서론 본론 1. 일본 재심사 제도의 역사 2. 재심사 제도 개정의 주요 내용 3. 제조 판매 후 데이터베이스 조사 신설에 따른 제반사항 4. 규제과학센터 설립 5. 시사점 고찰 및 결론 참고문헌
키워드
drug re-examination systempost-marketing studyreal world dataJapan
한국보건사회약료경영학회 [Korean Academy of Social & Managed Care Phemacy]
설립연도
2009
분야
의약학>약학
소개
본 학회는 비영리 학술단체로서 환자의 삶의 질 향상을 위한 약료(pharmaceutical care)가 보장될 수 있도록 약료경영약학(managed care pharmacy)을 발전시키는 데 궁극 목적을 두고 다음과 같은 활동을 전개하여 사회에 기여하며 회원 상호간의 친목을 도모한다.
간행물
간행물명
한국보건사회약료경영학회지 [Journal of Korean Academy of Managed Care Pharmacy]